Cost-effectiveness of infliximab versus conventional combination treatment in methotrexate-refractory early rheumatoid arthritis: 2-year results of the register-enriched randomised controlled SWEFOT trial

OBJECTIVE: To estimate the incremental cost-effectiveness of infliximab versus conventional combination treatment over 21 months in patients with methotrexate-refractory early rheumatoid arthritis. METHODS: In this multicentre, two-arm, parallel, randomised, active-controlled, open-label trial, rheu...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Ann Rheum Dis
Main Authors: Eriksson, Jonas K, Karlsson, Johan A, Bratt, Johan, Petersson, Ingemar F, van Vollenhoven, Ronald F, Ernestam, Sofia, Geborek, Pierre, Neovius, Martin
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Publishing Group 2015
Assuntos:
Clinical and Epidemiological Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4431324/
https://ncbi.nlm.nih.gov/pubmed/24737786
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/annrheumdis-2013-205060
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados